Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU); SYNB1934 Advances to Phase 3
October 18, 2022 06:59 ET
|
Synlogic, Inc.
Positive results include clinically meaningful Phe reductions, with a 60% response rate and 42% reduction in plasma Phe among responders across the study population Consistent, positive measures of...
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
September 26, 2022 09:00 ET
|
Sorrento Therapeutics, Inc.
Phase 2 trial of RTX for OAK pain completed enrollment with last patient (n=120) dosedNo limiting toxicities have been encountered during the trial to date. Patients are now being monitored for...
Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
September 01, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian...
View Smart Windows Selected for Phase Two of The Interlock, a Large-Scale, Mixed-Use Project Developed by SJC Ventures in Atlanta
August 29, 2022 07:00 ET
|
View, Inc.
ATLANTA and MILPITAS, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- View, Inc. (NASDAQ: VIEW), the leader in smart building technologies, announced its Smart Windows have been selected for phase two of...
Baby Shinja ($BSHINJA) Prepares to Enter Phase 2, Following Certik Audit
August 19, 2022 19:15 ET
|
Baby Shinja
BOSTON, MA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- As news begins to trickle out about Ethereum’s long-anticipated Merge upgrade to proof-of-stake, it’s worth pointing out that revolutionary ...
Algernon Pharmaceuticals Reports Additional Positive Data From its Phase 2 Study of Ifenprodil for IPF and Chronic Cough
July 28, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian...
Algernon Pharmaceuticals Hits Co-Primary Endpoint in its Phase 2 Study of Ifenprodil for Idiopathic Pulmonary Fibrosis and Chronic Cough
July 18, 2022 08:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, July 18, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage Canadian...
Algernon Announces Patients Requested Ongoing Supply of Ifenprodil after IPF and Chronic Cough Phase 2 Study Ended
June 21, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage...
Algernon Pharmaceuticals Announces Database Lock in Phase 2 Study of IPF and Chronic Cough
June 13, 2022 07:00 ET
|
Algernon Pharmaceuticals
VANCOUVER, British Columbia, June 13, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGWO) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Recardio's Positive Phase 2 Results Presented as Latebreaker at World Congress on Acute Heart Failure 2022 in Madrid
May 23, 2022 14:00 ET
|
Recardio Inc.
SAN FRANCISCO, May 23, 2022 (GLOBE NEWSWIRE) -- Entitled "Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptinin Combination with Filgrastim in Early...